IMUX - NASDAQ
Immunic, Inc.
$14.43
+0.63%Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
At a Glance
Live Snapshotimux
Cash at End of Period
Last Annual Value
15.48M
3-Year CAGR
-47%
5-Year CAGR
-34%
10-Year CAGR
-15%
Immunic, Inc. Competitors Analysis of Cash at End of Period
| Company | Cash at End of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Immunic, Inc. NASDAQ:IMUX | 15.48M | -30.8% | -29.2% | -12.7% | |
 Biomea Fusion, Inc. NASDAQ:BMEA | 56.18M | -31.8% | -17.4% | N/A | |
 Werewolf Therapeutics, Inc. NASDAQ:HOWL | 57.95M | -28.0% | -18.3% | N/A | |
 ALX Oncology Holdings Inc. NASDAQ:ALXO | 16.44M | -9.9% | -46.2% | N/A | |
 MindWalk Holdings Corp. NASDAQ:HYFT | 10.79M | 8.9% | -23.7% | 41.3% | |
 ImageneBio Inc NASDAQ:IMA | 94.53M | -7.6% | -16.5% | N/A | |
 Unicycive Therapeutics, Inc. NASDAQ:UNCY | 29.20M | 44.4% | 12.0% | N/A | |
 Adicet Bio, Inc. NASDAQ:ACET | 41.79M | -36.0% | -31.5% | -4.6% | |
 Lite Strategy, Inc. NASDAQ:LITS | 18.01M | 2.1% | 16.1% | N/A | |
 PMV Pharmaceuticals, Inc. NASDAQ:PMVP | 37.98M | -0.5% | -26.2% | N/A | |
 Relmada Therapeutics, Inc. NASDAQ:RLMD | 3.50M | -5.1% | -39.9% | 7.4% |
Immunic, Inc. Fair Value Envelope
Related Guides
Continue your IMUX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.